Latest News and Press Releases

Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments

Essential Pharma reaches agreement with AGC Biologics for late phase clinical manufacturing of its immunotherapy candidate for the treatment of high-risk neuroblastoma Egham, UK and Copenhagen,...

Optical genome mapping was used in three publications to successfully assess genome integrity in stem cells, CAR-T cells, and iPSCs.

Essential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastoma First development-stage asset to be added to the Essential Pharma...

Press Release Renaissance Pharma launches today and announces the in-licensing of Hu14.18K322A (Hu14.18) from St. Jude Children’s Research Hospital for the treatment of High-Risk Neuroblastoma ...

Press Release Renaissance Pharma launches today and announces the in-licensing of Hu14.18K322A (Hu14.18) from St. Jude Children’s Research Hospital for the treatment of High-Risk Neuroblastoma ...

New York, USA, April 20, 2023 (GLOBE NEWSWIRE) -- Neuroblastoma Market to Grow at a Substantial Growth Rate, Predicts DelveInsight | Y-mabs therapeutics, Clarity Pharmaceuticals, K C...

New York, USA, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Neuroblastoma Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 25+ Companies Working in the Domain DelveInsight’s...

- Findings from the Phase 1 study provide evidence that AUTO6 induces clinical activity in this solid tumor setting without inducing on-target off-tumor toxicity - AUTO6NG builds on this approach...

LONDON, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, and Noile-Immune...